Mirkka Sarparanta1, Jacob Pourat2, Kathryn E Carnazza2, Jun Tang2, Navid Paknejad3, Thomas Reiner4, Mauri A Kostiainen5, Jason S Lewis6. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Chemistry, Radiochemistry, University of Helsinki, Helsinki, Finland. Electronic address: mirkka.sarparanta@helsinki.fi. 2. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Molecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiology, Weill Cornell Medical College, New York, NY, USA. 5. Biohybrid Materials Group, Department of Bioproducts and Biosystems, Aalto University, Espoo, Finland. 6. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiology, Weill Cornell Medical College, New York, NY, USA; Department of Pharmacology, Weill Cornell Medical College, New York, NY, USA.
Abstract
METHODS: We have developed a nuclear and fluorescence labeling strategy for nanocrystalline cellulose (CNC), an emerging biomaterial with versatile chemistry and facile preparation from renewable sources. We modified CNC through 1,1'-carbonyldiimidazole (CDI) activation with radiometal chelators desferrioxamine B and 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), allowing for the labeling with zirconium-89 (t½ = 78.41 h) and copper-64 (t½ = 12.70 h), respectively, for non-invasive positron emission tomography (PET) imaging. The far-red fluorescent dye Cy5 was added for ex vivo optical imaging, microscopy and flow cytometry. The multimodal CNC were evaluated in the syngeneic orthotopic 4T1 tumor model of human stage IV breast cancer. RESULTS: Modified CNC exhibited low cytotoxicity in RAW 264.7 macrophages over 96 h, and high radiolabel stability in vitro. After systemic administration, radiolabeled CNC were rapidly sequestered to the organs of the reticulo-endothelial system (RES), indicating immune recognition and no passive tumor targeting by the enhanced permeability and retention (EPR) effect. Modification with NOTA was a more favorable strategy in terms of radiolabeling yield, specific radioactivity, and both the radiolabel and dispersion stability in physiological conditions. Flow cytometry analysis of Cy5-positive immune cells from the spleen and tumor corroborated the uptake of CNC to phagocytic cells. CONCLUSIONS: Future studies on the in vivo behavior of CNC should be concentrated on improving the nanomaterial stability and circulation half-life under physiological conditions and optimizing further the labeling yields for the multimodality imaging strategy presented. ADVANCES IN KNOWLEDGE: Our studies constitute one of the first accounts of a multimodality nuclear and fluorescent probe for the evaluation of CNC biodistribution in vivo and outline the pitfalls in radiometal labeling strategies for future evaluation of targeted CNC-based drug delivery systems. IMPLICATIONS FOR PATIENT CARE: Quantitative and sensitive molecular imaging methods provide information on the structure-activity relationships of the nanomaterial and guide the translation from in vitro models to clinically relevant animal models.
METHODS: We have developed a nuclear and fluorescence labeling strategy for nanocrystalline cellulose (CNC), an emerging biomaterial with versatile chemistry and facile preparation from renewable sources. We modified CNC through 1,1'-carbonyldiimidazole (CDI) activation with radiometal chelators desferrioxamine B and 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), allowing for the labeling with zirconium-89 (t½ = 78.41 h) and copper-64 (t½ = 12.70 h), respectively, for non-invasive positron emission tomography (PET) imaging. The far-red fluorescent dye Cy5 was added for ex vivo optical imaging, microscopy and flow cytometry. The multimodal CNC were evaluated in the syngeneic orthotopic 4T1 tumor model of human stage IV breast cancer. RESULTS: Modified CNC exhibited low cytotoxicity in RAW 264.7 macrophages over 96 h, and high radiolabel stability in vitro. After systemic administration, radiolabeled CNC were rapidly sequestered to the organs of the reticulo-endothelial system (RES), indicating immune recognition and no passive tumor targeting by the enhanced permeability and retention (EPR) effect. Modification with NOTA was a more favorable strategy in terms of radiolabeling yield, specific radioactivity, and both the radiolabel and dispersion stability in physiological conditions. Flow cytometry analysis of Cy5-positive immune cells from the spleen and tumor corroborated the uptake of CNC to phagocytic cells. CONCLUSIONS: Future studies on the in vivo behavior of CNC should be concentrated on improving the nanomaterial stability and circulation half-life under physiological conditions and optimizing further the labeling yields for the multimodality imaging strategy presented. ADVANCES IN KNOWLEDGE: Our studies constitute one of the first accounts of a multimodality nuclear and fluorescent probe for the evaluation of CNC biodistribution in vivo and outline the pitfalls in radiometal labeling strategies for future evaluation of targeted CNC-based drug delivery systems. IMPLICATIONS FOR PATIENT CARE: Quantitative and sensitive molecular imaging methods provide information on the structure-activity relationships of the nanomaterial and guide the translation from in vitro models to clinically relevant animal models.
Authors: Gregory W Severin; Jesper T Jørgensen; Stefan Wiehr; Anna-Maria Rolle; Anders E Hansen; Andreas Maurer; Mike Hasenberg; Bernd Pichler; Andreas Kjær; Andreas I Jensen Journal: Nucl Med Biol Date: 2014-11-22 Impact factor: 2.408
Authors: Khaled A Mahmoud; Jimmy A Mena; Keith B Male; Sabahudin Hrapovic; Amine Kamen; John H T Luong Journal: ACS Appl Mater Interfaces Date: 2010-10 Impact factor: 9.229
Authors: Marnix A Lameijer; Jun Tang; Matthias Nahrendorf; Robert H J Beelen; Willem J M Mulder Journal: Expert Rev Mol Diagn Date: 2013-07 Impact factor: 5.225
Authors: Hanna Valo; Suvi Arola; Päivi Laaksonen; Mika Torkkeli; Leena Peltonen; Markus B Linder; Ritva Serimaa; Shigenori Kuga; Jouni Hirvonen; Timo Laaksonen Journal: Eur J Pharm Sci Date: 2013-03-14 Impact factor: 4.384
Authors: Kenji Yokoi; Tomonori Tanei; Biana Godin; Anne L van de Ven; Masaki Hanibuchi; Aika Matsunoki; Jenolyn Alexander; Mauro Ferrari Journal: Cancer Lett Date: 2013-12-24 Impact factor: 8.679
Authors: Brian M Zeglis; Charles B Davis; Dalya Abdel-Atti; Sean D Carlin; Aimei Chen; Robert Aggeler; Brian J Agnew; Jason S Lewis Journal: Bioconjug Chem Date: 2014-11-26 Impact factor: 4.774
Authors: Surachet Imlimthan; You Cheng Khng; Outi Keinänen; Wenzhong Zhang; Anu J Airaksinen; Mauri A Kostiainen; Brian M Zeglis; Hélder A Santos; Mirkka Sarparanta Journal: Small Date: 2021-03-18 Impact factor: 13.281
Authors: Manja Kubeil; Irma Ivette Santana Martínez; Michael Bachmann; Klaus Kopka; Kellie L Tuck; Holger Stephan Journal: Pharmaceuticals (Basel) Date: 2022-03-31